Eli Lilly's GLP-1 Penetration, Volume Seen in Early Stages, RBC Capital Markets Says

12:04 PM EDT, 10/30/2026 (MT Newswires) -- Eli Lilly (LLY) posted an "impressive" Q3 supported by strong GLP-1 sales and a $5 billion guidance raise exceeding expectations, RBC Capital Markets said in a Thursday note. The firm noted GLP-1 market penetration and volume remain in the early stages despite lingering pricing concerns. RBC raised its 2027 revenue estimate to $108.2 billion from $105.5 billion, and its EPS estimate to $51.68 from $48.29. The firm said Mounjaro sales in the US are maturing and continue to grow in absolute terms, maintaining more than half of the US type 2 diabetes incretin analog market. Foundayo growth remains modest, but the firm said new starts are skewing toward the targeted lower-body-mass-index population and that a potential type 2 diabetes indication represents the next material inflection point. RBC Capital Markets maintained its outperform rating on Eli Lilly and raised its price target to $1,600 from $1,500. Eli Lilly shares were 3.5% higher in Friday trading. Price: 1421.68, Change: +47.97, Percent Change: +3.49